Economic Impact of and Treatment Options for Type 2 DiabetesByJan D. Hirsch, BSPharm, PhD,Candis M. Morello, PharmD, CDEAugust 21st 2017
Strategies for Addressing the Cost of Nonadherence in DiabetesByCandis M. Morello, PharmD, CDE,Jan D. Hirsch, BSPharm, PhDAugust 21st 2017
Overview of the Cardiovascular Benefit With Diabetic Agents and Novel Combination Products for Type 2 DiabetesByCandis M. Morello, PharmD, CDEAugust 21st 2017
Utilizing Advances in Diabetes and Targeting Medication Adherence to Enhance Clinical Outcomes and Manage Costs for Type 2 Diabetes PosttestByAugust 21st 2017
